The overall rate of GSH synthesis is controlled by several factors including: (i) availability of the substrate mainly L-cysteine (Anderson and Meister, 1983)
Access this chapter Similar content being viewed by others Abbreviations 4-HNE: 4-Hydroxynonenal 8-OH-dG: 8-hydroxy-20-deoxyguanosine AKR: Aldo-keto reductase ATF-2: Activating transcription factor ATM: Ataxia telangiectasia mutated CAT: Catalase CBR1: Carbonyl reductase 1 G6PD: Glucose-6-phosphate dehydrogenase GCL: Glutamate cysteine ligase GGT: Gamma-glutamyl transferase GPX: Glutathione peroxidase GS: Glutathione synthetase GSH and GSSG: Reduced and oxidized glutathione GSR: Glutathione reductase GST: Glutathione S-transferases HCC: Hepatocellular carcinoma HIF: Hypoxia-inducible factors HMOX: Heme oxygenase HNF4: Hepatocyte nuclear factor alpha MDA: Malondialdehyde MDR: Multidrug resistance protein MT: Metallothionein NADPH: Nicotinamide adenine dinucleotide phosphate NFE2L2: Nuclear factor (erythroid-derived 2)-like 2 NF-kB: Nuclear factor kB NQO1: NADPH quinone oxidoreductase 1 PI3K: Phosphoinositide 3 kinase PLC: Phospholipase C PPAR: Peroxisome proliferator-activated receptors PRX: Peroxiredoxin PTEN: Phosphatase and tensin homolog PTGR: Prostaglandin reductase RAR: Retinoic acid receptors RNS: Reactive nitrogen species ROS: Reactive oxygen species SOD: Superoxide dismutase TRX: Thioredoxin TXNR: Thioredoxin reductase References Albrethsen J, Miller LM, Novikoff PM, Angeletti RH
Transform your skin and embrace a more radiant you with the Skin Brightening IV Drip at Faces By Bae
Although novel therapeutic strategies and targeted therapies, including intraperitoneal administration, poly (ADP-ribose) polymerase (PARP) inhibitors, and anti-angiogenic agents, have been introduced, the five-year survival rate for patients with advanced ovarian cancer (OC) remains approximately 30%
The findings provide valuable insights to optimize metformins therapeutic application in PCOS treatment, enabling safer pharmacologic management and improved patient prognoses
Because this combination is not approved yet, healthcare providers will eventually closely monitor patients for gastrointestinal side effects, such as nausea, vomiting, or constipation, and adjust doses accordingly to maximize benefits while minimizing discomfort
